Evidence quality 4.63/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 4/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
● your factors — click this risk ▾ to reveal
- Your factors
≈ As likely as
Perceived
Parkinson’s sits in an odd middle zone on the fear-attention scale. It has the cultural signature of a "serious older-person disease" — tremor, the stooped posture, a handful of famous diagnoses from Muhammad Ali to Michael J. Fox to Ozzy Osbourne — but unlike Alzheimer’s, most adults under 60 rarely think about their own lifetime odds of developing it. When asked to guess, the typical answer is "pretty rare, maybe 1 in 500 or 1 in 1,000". The actual lifetime risk, per the cited Lancet epidemiology review, is approximately 5% — closer to 1 in 20 — which is far higher than the intuition but still below dementia. Public awareness of Parkinson’s as a disease is high; awareness of personal odds is systematically low.
Rough estimate: Most adults guess their personal lifetime PD risk at ~1 in 500 or lower
Source: editorial intuition, not polled
Actual
~11.8 million people living with Parkinson's worldwide (2021); ~90,000 new US cases per year
general adults
Show derivation
Taken directly from the entry’s cited Lancet review (Ben-Shlomo et al., 2024), which states that "the lifetime risk of Parkinson’s disease is approximately 5%". That review is global in scope and states the figure as a general-adult lifetime risk (used there as the baseline assumption in a population-level prevention calculation). It is the only cited source that states a lifetime probability, so the headline is grounded on it rather than on any incidence-compounding derivation. The supporting counts confirm the order of magnitude: the Parkinson’s Foundation reports ~1.1 million Americans living with PD and ~90,000 new US diagnoses per year, the WHO fact sheet reports over 8.5 million living with PD globally in 2019 (doubled over 25 years), and GBD 2021 (Luo et al.) reports 11.77 million global prevalent cases in 2021 — all consistent with a several-percent lifetime probability given PD’s long ~12–15 year residence time and strong age concentration above 65. The uncertainty band 0.02 to 0.06 reflects the "approximately" qualifier on the 5% figure and the substantial geographic variation the same review documents (prevalence estimates "vary considerably across geographical regions"; competing mortality in lower-income settings removes many adults from the denominator before peak PD-risk ages), and the fact that PD is systematically underdiagnosed (per the Parkinson’s Foundation, roughly 40% of US patients do not see a neurologist). Critically, this is INCIDENCE — the probability of being diagnosed with PD — not the probability of dying from PD. Parkinson’s is a chronic progressive disease; most patients die with it, not directly of it, and the proximal cause of death is usually aspiration pneumonia, cardiovascular disease, or a fall complication rather than PD-coded mortality.
Caveats: Two framing issues shape the headline number. First, this is INCIDENCE — the pro…
Two framing issues shape the headline number. First, this is INCIDENCE — the probability of being diagnosed with Parkinson’s disease in one’s lifetime — not mortality. PD is a chronic progressive disease with a typical 12-15 year course from diagnosis in high-income settings, and most patients die WITH it rather than OF it; the proximal cause on most death certificates is aspiration pneumonia, cardiovascular disease, or a fall complication. The WHO figure of 329,000 global PD deaths per year is therefore a floor, not a ceiling. Second, PD is systematically underdiagnosed: roughly 40% of US patients with PD do not see a neurologist at all, per the Parkinson’s Foundation, so diagnosed incidence is lower than true biological incidence. The headline ~1-in-20 (5%) figure is the general-adult lifetime risk stated by the cited Lancet epidemiology review; it is global and not sex-specific. Men carry a higher risk than women (incidence ratio ~1.4–1.5:1), but no cited source states a separate lifetime probability for either sex, so this entry does not publish one; the true figure for a given reader varies with sex, geography, and competing mortality. Personal factor multipliers are illustrative relative risks from the epidemiological literature and overlap with each other — family history, LRRK2 status, and pesticide exposure are not independent dimensions of risk.
How the risk varies
The headline figure averages across very different situations. Here’s how the probability varies by scenario or context:
1 in 20 · 5.0%
The ~5% general-adult lifetime risk stated by the cited Ben-Shlomo et al. Lancet review; global in scope. Men carry higher risk than women (incidence ratio ~1.4:1 per the same review, ~1.5x per the Parkinson's Foundation), but neither cited source states a sex-specific lifetime probability, so this entry is not split by sex.
1 in 13 · 8.0%
Occupational exposure to paraquat, rotenone, and organochlorines is the strongest established environmental risk factor; the cited Lancet review reports RR ~1.5-2.0 vs baseline. Applying the mid-range ~1.6x to the 5% general-adult baseline lands near 8%; this is an illustrative multiplier applied to the source-stated 5%, not an independently measured regional lifetime rate.
Bar length and shade rank these scenarios against each other, not against other risks. The exact odds are shown beside each.
Related risks
Other risks on similar themes — for exploring related fears.
End-stage kidney disease
What are the lifetime odds of developing end-stage kidney disease requiring dialysis or transplant?
Pick challenger
Roughly 11 million people were living with Parkinson’s disease worldwide as of the most recent estimate (2021), up from about 3 million in 1990 — the WHO puts global prevalence as having doubled in just the past 25 years, with disability and death, in the WHO’s language, rapidly increasing. In the US, the Parkinson’s Foundation counts about 1.1 million Americans with PD and ~90,000 new diagnoses per year. The cited Lancet epidemiology review puts the lifetime risk at approximately 5% — roughly 1 in 20 — a general-adult, global figure rather than a sex- or country-specific one. That puts Parkinson’s below lifetime dementia risk but well above the fears most people worry about actively — on the order of thousands of times the lifetime odds of dying in a plane crash for a regular flyer, and several times the lifetime odds of dying in a car crash. Note that this is the probability of developing PD, not of dying from it: most people with Parkinson’s die with the disease, not directly of it, and the number coded on the death certificate is usually aspiration pneumonia or cardiovascular disease.
The interesting thing about Parkinson’s in the risk-factor literature is the smoking paradox. Across more than five decades and dozens of cohort and case-control studies, regular cigarette smokers have roughly half the PD risk of never-smokers, with a clear dose-response: more pack-years, lower risk. Coffee drinking shows a similar ~30% relative-risk reduction, stronger in men. Nobody recommends smoking as Parkinson’s prevention — the smoking mortality from lung cancer, COPD, and cardiovascular disease dwarfs the PD benefit by about two orders of magnitude — but the signal is one of the most robust inverse associations in chronic-disease epidemiology, and the mechanism is still actively debated (nicotine neuroprotection? a shared personality trait correlated with both smoking uptake and resistance to PD? selection bias from differential mortality removing smokers from the denominator before they reach peak PD-risk ages?). The Dorsey et al. Parkinson-pandemic paper explicitly lists declining smoking rates as one of the factors that could push global PD cases from 12 million to 17 million by 2040.
Where the number doesn’t apply: Parkinson’s is highly heterogeneous. The male:female ratio sits around 1.4-1.5:1 and the mechanism is not fully understood — women have longer life expectancy and ought to accumulate more PD on pure age-structure grounds, so the persistent male excess is a genuine biological asymmetry, not an artefact. Agricultural workers with chronic exposure to paraquat, rotenone, or organochlorine pesticides run roughly 1.5-2.0× baseline risk; this is the strongest established environmental factor and the clearest counterexample to the “idiopathic” label that applies to most cases. On the genetic side, carriers of the LRRK2 G2019S mutation — most common in Ashkenazi Jewish and North African Berber populations — have about a 10× relative risk and a cumulative incidence near 50% by age 80. Most PD, however, is idiopathic: no single environmental or genetic cause is identifiable for any individual case, and the bulk of lifetime risk is absorbed into the plain fact of living long enough to reach the ages where the substantia nigra starts losing dopaminergic neurons faster than it can compensate.
Related tidbits
A typical adult's lifetime odds of developing Parkinson's disease are about 1 in ~125 lifetime (global adult). Most people guess their personal risk at 1 in 500 or lower, but prevalence has roughly doubled in a generation.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
2/5 sources independently verified verbatim against the cited source
-
[1] Parkinson's Foundation — Parkinson's Disease Statistics Verified
Parkinson's Disease Statistics- Statistic
~1.1 million Americans living with PD; ~90,000 new US cases/year; men 1.5x more likely than women; 4% diagnosed before age 50- Excerpt
“"An estimated 1.1 million people in the U.S. are living with Parkinson’s disease (PD). [...] Nearly an estimated 90,000 people in the U.S. are diagnosed with PD each year. [...] The incidence of Parkinson’s disease increases with age, but an estimated 4% of people with PD are diagnosed before age 50. [...] Men are 1.5 times more likely to have Parkinson’s disease than women. [...] More than 10 million people worldwide are estimated to be living with PD." ”
- Source data from
- 2024-01-01
- Accessed
- 2026-04-11 · archived copy
- Verification
- Excerpt independently re-fetched and confirmed word-for-word against the cited source during our grounding audit.
- Calculation
- This source supplies the supporting counts (~1.1M Americans living with PD, ~90,000 new US diagnoses/year, men 1.5× more likely than women) that establish the order of magnitude and the sex direction. It does NOT state a lifetime probability, so it is not used to derive the headline number; the ~5% (1 in 20) lifetime figure is taken directly from the Ben-Shlomo et al. Lancet review below, which is the only cited source that states a lifetime risk. The Foundation’s 1.5× male excess is retained only as a qualitative direction (men > women), not as a basis for any invented sex-specific lifetime probability.
- Independence
- Parkinson’s Foundation synthesizes CDC/NCHS vital registration, the Parkinson’s Prevalence Project (Marras et al., 2018) cohort, and Medicare claims. Partially dependent with any GBD-derived global figure.
-
[2] World Health Organization — Parkinson disease — fact sheet Verified
Parkinson disease — fact sheet- Statistic
Over 8.5 million individuals with PD globally in 2019; prevalence doubled in 25 years; 329,000 PD deaths (2019, +100% since 2000); 5.8 million DALYs (+81% since 2000)- Excerpt
“"The prevalence of PD has doubled in the past 25 years. Global estimates in 2019 showed over 8.5 million individuals with PD. [...] PD resulted in 5.8 million disability adjusted life years (DALYs), an increase of 81% since 2000 and caused 329 000 deaths, an increase of over 100% since 2000. [...] Globally, disability and death due to PD are rapidly increasing." ”
- Source data from
- 2023-08-09
- Accessed
- 2026-04-11 · archived copy
- Verification
- Excerpt independently re-fetched and confirmed word-for-word against the cited source during our grounding audit.
- Calculation
- 8.5M prevalent global cases across ~5.5B adults in 2019 = ~0.15% point prevalence in the global adult population. Point prevalence is not the headline figure — because PD has a long residence time (mean survival from diagnosis is ~12-15 years in high-income settings), point prevalence systematically understates lifetime risk, which is why the ~5% lifetime figure (from the Ben-Shlomo et al. Lancet review) sits well above this point-prevalence snapshot. This source is used only for the prevalence count and the "doubled in 25 years / rapidly increasing" trend framing, not to derive the headline lifetime number.
- Independence
- WHO Parkinson fact sheet draws on GBD 2019 (Institute for Health Metrics and Evaluation) and the 2022 WHO technical brief on Parkinson disease. Partially dependent with Dorsey et al. below, which was an input to GBD’s Parkinson estimates.
-
[3] Luo et al. — Frontiers in Aging Neuroscience — Global, regional, national epidemiology and trends of Parkinson's disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021
Global, regional, national epidemiology and trends of Parkinson's disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021- Statistic
Global prevalent Parkinson's disease cases reached 11.77 million in 2021 (95% UI 10.44-13.42 million), an increase of 273.76% since 1990- Excerpt
“"The prevalent cases of Parkinson’s disease in 2021 were 11.77 (95% UI: 10.44-13.42) million [...] increased by 273.76% (95% UI: 260.22-287.26%) from 1990." ”
- Source data from
- 2025-01-10
- Accessed
- 2026-07-03 · archived copy
- Calculation
- This GBD 2021 systematic analysis is the direct source for the native.display "~11.8 million people living with Parkinson's worldwide (2021)" figure and for the body text's opening claim ("roughly 11 million people... up from about 3 million in 1990"): a 273.76% increase since 1990 implies a 1990 baseline of 11.77 / 3.7376 ≈ 3.15 million, consistent with "about 3 million in 1990" in the body text. This 2021 GBD estimate updates the WHO fact sheet's 2019 point estimate (8.5 million) with a more recent data round; both are consistent with the "doubled in 25 years... rapidly increasing" WHO framing above.
- Independence
- GBD 2021-based reanalysis, methodologically continuous with (not fully independent of) the WHO and Dorsey et al. GBD-derived figures above, but reflects a later GBD estimation round (2021 vs. 2019) with materially updated case counts.
-
[4] Dorsey, Sherer, Okun, Bloem — Journal of Parkinson's Disease — The Emerging Evidence of the Parkinson Pandemic
The Emerging Evidence of the Parkinson Pandemic- Statistic
PD doubled from ~3M to >6M (1990-2015); projected >12M by 2040; up to 17M under declining-smoking and industrialization scenarios- Excerpt
“"From 1990 to 2015, the number of people with Parkinson disease doubled to over 6 million. [...] This number is projected to double again to over 12 million by 2040. [...] Additional factors, including increasing longevity, declining smoking rates, and increasing industrialization, could raise the burden to over 17 million." ”
- Source data from
- 2018-12-18
- Accessed
- 2026-04-11 · archived copy
- Calculation
- Used to anchor the trend line (doubling 1990-2015, doubling again by 2040) and the note that declining smoking rates are projected to increase PD burden. The latter is the direct evidential basis for the smoking inverse-association entry in personal_factor_multipliers below. Note: the paper’s 2015 figure of 6.2M and the WHO/GBD 2019 figure of 8.5M are consistent with the doubling-per-25-years trajectory.
- Independence
- Dorsey et al. 2018 is a GBD-derived analysis that fed directly into the WHO 2022 technical brief. Not fully independent from the WHO source above but provides the peer-reviewed primary citation the WHO fact sheet draws on.
-
[5] Ben-Shlomo, Darweesh, Llibre-Guerra, Marras, San Luciano, Tanner — The Lancet (via PMC) — The epidemiology of Parkinson's disease
The epidemiology of Parkinson's disease- Statistic
Lifetime risk of Parkinson's disease is approximately 5%; male:female incidence ratio ~1.4:1; smoking shows dose-response inverse association with PD; pesticides (paraquat, rotenone) biochemically linked- Excerpt
“"the lifetime risk of Parkinson’s disease is approximately 5% [...] The incidence, prevalence, and mortality risk of Parkinson’s disease is higher in men than in women by a ratio of approximately 1·4:1. [...] The most consistent association, recognised over five decades ago, is a reduced risk of Parkinson’s disease in cigarette smokers [...] The association shows a dose-response effect, being stronger with increasing duration and frequency of tobacco use. [...] Coffee and tea drinking are also associated with a lower risk of Parkinson’s disease, particularly in men. [...] Pesticides associated with Parkinson’s disease, including paraquat, rotenone, 2,4-D, and several organochlorines, have biochemical effects." ”
- Source data from
- 2024-04-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- Primary anchor for BOTH the headline lifetime number and the personal_factor_multipliers block. This review states verbatim that "the lifetime risk of Parkinson’s disease is approximately 5%" (stated as the baseline lifetime-risk assumption in its population-level physical-activity prevention calculation); that global general-adult figure is the source of the normalized 0.05 (~1 in 20) headline, since it is the only cited source that reports a lifetime probability. The 1.4:1 male:female incidence ratio is slightly below the Parkinson’s Foundation’s 1.5× figure; both are within the meta-analytic range. The smoking inverse association of ~0.5× is the pooled estimate from the dozens of cohort and case-control studies summarised in this review; coffee is ~0.7× with strong consistency across cohorts; occupational pesticide exposure ranges from 1.5× to 2.0× depending on the chemical and the exposure definition. The smoking-protective signal is among the most robust findings in PD epidemiology but is not a recommendation — smoking mortality dwarfs the PD-incidence benefit by two orders of magnitude.
- Independence
- This Lancet review synthesises decades of PD case-control, cohort, and Mendelian-randomisation evidence. Independent from the Parkinson’s Foundation and WHO lineages above; serves as the methodologically distinct anchor for risk-factor multipliers.







